Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

H, Al-Sudani; Y, Ni; P, Jones; H, Karakilic; L, Cui; LDS, Johnson; PG, Rose; A, Olawaiye; RP, Edwards; RA, Uger; GHY, Lin; H, Mahdi

doi:10.1038/s41698-023-00418-4

Public

Targeting CD47-SIRPa axis shows potent preclinical anti-tumor activity as monotherapy and synergizes with PARP inhibition.

Published in NPJ precision oncology • Jul 19, 2023

Authors:

Al-Sudani H

Ni Y

Jones P

Abstract

The objective was to correlate CD47 gene expression with resistance to immune checkpoint inhibitors (ICI) in tumor tissue of gynecological cancer (GC). Further, we sought to assess the efficacy of targeting CD47 pathway alone and in combination in pre-clinical ovarian cancer (OC) models. We performe...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!